Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company") (NASDAQ
MKT: PTX), a specialty pharmaceutical company, today announced it has
signed a lease for new corporate headquarters at 10 North Park Place in
The new headquarters will be occupied in mid-May and is a key step
towards the achievement of several corporate initiatives, including
improving the efficiency of the Company's operational infrastructure by
consolidating office locations and hiring and retaining experienced
employees. The Company has shifted its emphasis from horizontal
integration to focusing on its core sales and marketing strengths to
build a leading specialty pharmaceutical business.
Commenting on the new headquarters, Doug Drysdale, President and CEO of
Pernix said "Establishing Pernix's headquarters in Morristown, New
Jersey continues our efforts to build Pernix into a focused specialty
pharmaceutical company with an experienced management team that is
well-positioned for additional product acquisitions."
About Pernix Therapeutics Holdings, Inc.
Pernix Therapeutics is a specialty pharmaceutical company primarily
focused on the sales, marketing, manufacturing and development of
branded pharmaceutical products. The Company markets a portfolio of
branded products, including: CEDAX®, an antibiotic for middle ear
infections and a number of treatments for cough and cold conditions
including ZUTRIPRO®, REZIRA® and VITUZ®. The Company also markets
SILENOR, a non-narcotic product for the treatment of insomnia and
KHEDEZLA, a treatment for major depressive disorder. The Company
promotes its branded products to physicians through its Pernix sales
force and markets its generic portfolio through its wholly owned
subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals.
Founded in 1996, the Company is now based in Morristown, New Jersey.
Additional information about Pernix is available on the Company's
website located at www.pernixtx.com.
[ Back To NFVZone's Homepage ]